Drug intelligence / Profile preview

Carfem

Development stage: Unknown
Lead developer: Stevia Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Carfem is a hematinic supplement brand developed by Stevia Pharmaceuticals, primarily indicated for the treatment and prevention of iron deficiency anemia. The product line includes multiple formulations designed to address nutritional deficiencies and support erythropoiesis. Carfem capsules typically contain a combination of carbonyl iron, folic acid, vitamin B12 (cyanocobalamin), and zinc sulfate. The Carfem-XT variant is generally formulated as a tablet containing ferrous ascorbate, folic acid, and zinc. These components work synergistically to replenish elemental iron stores, support DNA synthesis in hematopoietic cells, and provide essential cofactors for red blood cell maturation.

Brand names: CarfemCarfem-XT
Other names: CarfemCarfem-XT

Targets

MTR (Methionine synthase)DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on Carfem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carfem.

Explore the full profile